2-(4-Amino-3-chloro-5-trifluoromethyl-benzyl)-4-oxo-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butyraldehyde → 3-(1-{4-(4-Amino-3-chloro-5-trifluoromethyl-phenyl)-3-[1-(3-dimethylamino-2,2-dimethyl-propyl)-1h-benzimidazol-2-yl]-butyryl}-piperidin-4-yl)-1,3,4,5-tetrahydro-1,3-benzodiazepin-2-one

HRID 1795060Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 1795060
[NH2:1][C:2]1[C:32]([C:33]([F:36])([F:35])[F:34])=[CH:31][C:5]([CH2:6][CH:7]([CH2:10][C:11](=[O:30])[N:12]2[CH2:17][CH2:16][CH:15]([N:18]3[CH2:24][CH2:23][C:22]4[CH:25]=[CH:26][CH:27]=[CH:28][C:21]=4[NH:20][C:19]3=[O:29])[CH2:14][CH2:13]2)[CH:8]=O)=[CH:4][C:3]=1[Cl:37].Cl.Cl.Cl.[CH3:41][N:42]([CH3:56])[CH2:43][C:44]([CH3:55])([CH3:54])[CH2:45][NH:46][C:47]1[C:48]([NH2:53])=[CH:49][CH:50]=[CH:51][CH:52]=1>CN(C=O)C>[NH2:1][C:2]1[C:32]([C:33]([F:36])([F:35])[F:34])=[CH:31][C:5]([CH2:6][CH:7]([C:8]2[N:46]([CH2:45][C:44]([CH3:55])([CH3:54])[CH2:43][N:42]([CH3:41])[CH3:56])[C:47]3[CH:52]=[CH:51][CH:50]=[CH:49][C:48]=3[N:53]=2)[CH2:10][C:11]([N:12]2[CH2:13][CH2:14][CH:15]([N:18]3[CH2:24][CH2:23][C:22]4[CH:25]=[CH:26][CH:27]=[CH:28][C:21]=4[NH:20][C:19]3=[O:29])[CH2:16][CH2:17]2)=[O:30])=[CH:4][C:3]=1[Cl:37]

Komponenten

4

Versuchsvorschrift

To a solution of 320 mg (0.596 mmol) 2-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-4-oxo-4-[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidin-1-yl]-butyraldehyde (Intermediate product 36) in 7 mL DMF was added 230 mg (0.695 mmol) N-(3-dimethylamino-2,2-dimethyl-propyl)-benzene-1,2-diamine-trihydrochloride (Intermediate product 37) and the mixture was stirred for 16 hours in an atmosphere of air. The reaction mixture was evaporated down i. vac. and the residue combined with EtOAc. The org. phase was washed with sat. aqueous sodium bicarbonate solution, dried over sodium sulphate and evaporated i. vac. The crude product was purified by column chromatography (silica gel, gradient dichloromethane/MeOH 20/1→10/1 v/v) then (Alox, neutral, activity II-III, gradient EtOAc/MeOH 100/0→40/1) and HPLC-MS (Zorbax Bonus C18 amide-phase 5 μm, gradient 0.15% formic acid in water/acetonitrile 10/90→90/10 v/v).

Aufarbeitung

  1. customThe reaction mixture was evaporated down i
  2. washphase was washed with sat. aqueous sodium bicarbonate solution
  3. dry with materialdried over sodium sulphate
  4. customevaporated i
  5. customThe crude product was purified by column chromatography (silica gel, gradient dichloromethane/MeOH 20/1→10/1 v/v)

Quellen und Nachweise

ORD-Eintrag
ord-191b5612f1e14799a7701feb5f3b0125
Quelldatensatz
uspto-grants-2006_04
Patentnummer
US07026312B2

Notizen zur Reaktion

Wird geladen…